CDSCO reviewing Cipla, Dr Reddys, others applications for Remdesivir on priority: Health Ministry Ruchika Sharma15 Jun 2020 4:00 PM ISTThe CDSCO is awaiting the data and is providing complete support to these companies. It has already waived off the requirement of local clinical...
Combating COVID-19: India to soon begin domestic production of Remdesivir drug Farhat Nasim14 Jun 2020 10:15 AM IST"Pharma companies have been directed to conduct Active-Post Marketing Surveillance of each case and prepare a report on the benefit or recovery of a...
Cipla to buy 21.85 pc stake in health-tech startup GoApptiv Ruchika Sharma10 Jun 2020 12:29 PM ISTIn the first stage, a subscription of 15,392 compulsorily convertible preference shares and purchase of 6,927 equity shares is expected to be closed...
DoP directs NPPA to verify documentary proof submitted by Cipla for Budesonide Farhat Nasim7 Jun 2020 1:09 PM ISTNew Delhi: Upholding the order of Delhi High Court to re-examine of the review applications moved by Cipla Ltd., the Department of...
Cipla, Hetero approach DCGI seeking waiver of Clinical Trial of Remdesivir in India: Report MD Bureau25 May 2020 4:59 PM ISTNew Delhi: With pharma companies across the country making efforts to get the first-mover advantage in bringing potential coronavirus treatments, two...
Cipla receives final approval for generic version of Migranal(Dihydroergotamine Mesylate Nasal Spray) with a Competitive Generic Therapy Designation Ruchika Sharma22 May 2020 1:44 PM ISTIt is indicated for the acute treatment of migraine headaches with or without aura
Cipla board nod to Rs 3000 crore fundraising proposal Farhat Nasim18 May 2020 6:20 PM ISTNew Delhi: Amidst the economic impact of the COVID-19 pandemic, drug major Cipla Ltd recently apprised that the company's board had approved...
Cipla files ANDA for generic version of Advair Diskus Ruchika Sharma18 May 2020 1:00 PM ISTIt is indicated as a twice-daily prescription medicine to treat asthma in patients aged four years and older
Cipla becomes 2nd firm to enter tie-up with Gilead to make remdesivir in India MD Bureau13 May 2020 9:23 AM ISTCipla will be permitted to manufacture the active pharmaceutical ingredient (API) and finished product, and market it in 127 countries including India...
Cipla gets USFDA EIR for Bommasandra API facility Ruchika Sharma10 May 2020 10:00 AM ISTBangalore: Cipla has announced that it has received Establishment Inspection Report (EIR) from USFDA for its API manufacturing facility in...
Cipla loses Cancer Drug patent battle to Amgen in US court Ruchika Sharma7 May 2020 1:58 PM ISTUS: In a major setback to drug major Cipla, the company has lost the patent infringement battle against Amgen Inc over the generic version of...
CSIR-IICT develops synthetic process for Favipiravir, transfers to Cipla MD Bureau1 May 2020 9:45 AM ISTCipla will be conducting the investigations prior to launching on this drug against Covid-19 in India. Cipla approached regulatory authority Drug...
